Literature DB >> 1493796

Molecular characterization of vascular smooth muscle decorin: deduced core protein structure and regulation of gene expression.

V K Asundi1, K L Dreher.   

Abstract

Two overlapping clones containing sequences homologous to bovine, human and chicken decorin have been recovered from poly A+ RNA isolated from rat vascular smooth muscle cells (VSMC) using cDNA cloning and reverse transcription-polymerase chain reaction (PCR) methodologies. Results of nucleotide sequence analysis performed on these clones demonstrated that they encode the complete mature rat decorin protein expressed by VSMC. Within the coding region, rat decorin exhibits 76% nucleotide sequence homology to human and bovine decorin, and 69% homologous to chicken decorin indicating a significant level of conservation among these species. This level of conservation among species was also maintained at the protein level with rat decorin being 77% homologous to its human, bovine and chicken homologues. As previously observed its human homologue, rat decorin, is made up of seven, tandem, leucine-rich repeat sequences. Furthermore, within the core of these repeats was the consensus protein sequence NKISK which has been proposed to be the fibronectin binding region of decorin (G. Schmidt et al., Biochem. J. 280, 411-414 (1991)). The vast majority of amino acid substitutions within rat decorin were of the conservative type. The highest frequency of amino acid substitutions were found to be localized within a hypervariable region located near the amino terminus of the decorin core protein. Unlike rat biglycan, rat decorin mRNA levels were found to increase significantly in density-arrested VSMC cultures. In contrast to rat biglycan gene expression, no quantitative differences in rat decorin mRNA levels were observed between proliferating VSMC and VSMC made quiescent through serum depletion. Finally, specific extracellular matrix (ECM) proteins were able to regulate the expression of decorin at the mRNA level in a slightly different manner than previously observed for biglycan.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1493796

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  7 in total

1.  Effects of decorin on the expression of alpha-smooth muscle actin in a human myofibroblast cell line.

Authors:  Tatsuya Nakatani; Eiko Honda; Sumio Hayakawa; Mayumi Sato; Ken Satoh; Masatoshi Kudo; Hiroshi Munakata
Journal:  Mol Cell Biochem       Date:  2007-10-20       Impact factor: 3.396

2.  Transforming growth factor beta may act as an autocrine-survival-promoting factor for transformed trophoblasts.

Authors:  C K Ho; H J Peng; S Y Wang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-04       Impact factor: 2.416

3.  De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells.

Authors:  M Santra; T Skorski; B Calabretta; E C Lattime; R V Iozzo
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

Review 4.  The response-to-retention hypothesis of early atherogenesis.

Authors:  K J Williams; I Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

5.  Differential expression of decorin by human malignant and benign vascular tumors.

Authors:  Henriikka H Salomäki; Annele O Sainio; Mirva Söderström; Sari Pakkanen; Jukka Laine; Hannu T Järveläinen
Journal:  J Histochem Cytochem       Date:  2008-04-14       Impact factor: 2.479

6.  Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways.

Authors:  Yunping Hu; Haiguo Sun; Rick T Owens; Jiansheng Wu; Yong Q Chen; Isabelle M Berquin; Donna Perry; Joseph T O'Flaherty; Iris J Edwards
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

7.  DCN deficiency promotes renal cell carcinoma growth and metastasis through downregulation of P21 and E-cadherin.

Authors:  Yongcan Xu; Qiuyuan Xia; Qiu Rao; Shanshan Shi; Qunli Shi; Henghui Ma; Zhenfeng Lu; Hui Chen; Xiaojun Zhou
Journal:  Tumour Biol       Date:  2015-11-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.